Institutional members access full text with Ovid®

Share this article on:

Subsets More Likely to Benefit From Surgery or Prophylactic Cranial Irradiation After Chemoradiation for Localized Non–Small-Cell Lung Cancer

Keith, Bruce M.D.; Vincent, Mark M.D.; Stitt, Larry M.Sc.; Tomiak, Anna M.D.; Malthaner, Richard M.D.; Yu, Edward M.D.; Truong, Pauline M.D.; Inculet, Richard M.D.; Lefcoe, Michael M.D.; Dar, A. Rashid M.D.; Kocha, Walter M.D.; Craig, Ian M.D.

American Journal of Clinical Oncology: December 2002 - Volume 25 - Issue 6 - p 583-587

After chemoradiation for localized non–small-cell lung cancer, surgery and prophylactic cranial irradiation (PCI) have been used as additional therapies. Less than a third of patients develop brain recurrences, or have local recurrence as their sole initial site of recurrence; these are groups that would benefit from PCI or surgery, respectively. Pretreatment identification of patients more likely to benefit from surgery or PCI would be useful. A retrospective analysis of 80 patients was performed to determine prognostic factors for such patterns of failure. Twenty-nine patients were subsequently selected for surgery in a nonrandomized manner. Seventeen patients had isolated local initial recurrence and 15 had brain recurrences. In multivariable analysis, female gender and elevated LDH were found to be risk factors for brain recurrence. In the subset with stage III disease (n = 76), squamous cell histology was a risk factor for isolated initial local recurrence in both univariable and multivariable analysis. It is possible to identify subsets that may show increased benefit from PCI or surgery.

From the London Regional Cancer Center, London, Ontario, Canada.

Address correspondence and reprint requests to Dr. Mark Vincent, LRCC, 790 Commissioners Road E., London, Ontario, Canada N6A4L6.

© 2002 Lippincott Williams & Wilkins, Inc.